Perspectives

Whitepaper Jul 28, 2026

Preparing for Universal Orphan Drug JCA Submissions

Our new whitepaper unpacks what "good" looks like for orphan JCA submissions covering comparative evidence strategy, real-world data readiness, and why the evidence-generation clock needs to start well before pivotal trials wrap up.

Take a look

Case Study Aug 8, 2021

Opinion Leader Identification and Engagement Planning

Whitepaper Aug 4, 2021

An Introduction to Planning for HTA for Tumour-Agnostic Cancer Drugs

View Jul 29, 2021

Precision vs Imprecision Oncology

Podcast Jul 28, 2021

Medical Affairs Unscripted | Executing Launch: Develop, Visualize, and Communicate with John Walsh, MD

Case Study Jul 19, 2021

Developing the First EMEA Cross-Functional Strategic Plan for an Autologous CAR T-Cell Therapy Asset with a Newly-Formed Launch Commercialization Team (T-30 months)

View Jul 13, 2021

Pharma Launch Team Ways of Working – Top Tips

View Jul 8, 2021

Silver Lining to Approval of Aducanumab?

Case Study Jun 22, 2021

Establishing an Organization-Wide Annual Strategic and Tactical Brand-Planning Process

Case Study May 25, 2021

Bioethics Landscape Analysis for Cell Therapies and Resultant Baseline Lexicon Development, as Part of Strategy Planning for Early-Asset Commercialization